Question · Q4 2025
Alex DeChello (Canaccord Genuity) inquired about CEO Everett Cunningham's initial assessment of Quanterix's core high-sensitivity proteomics and Spatial Biology businesses, focusing on effective strategies and potential near-term adjustments. DeChello also asked about the 2026 assay pipeline and the general availability timeline and early access feedback for the Simoa One platform.
Answer
President and CEO Everett Cunningham highlighted the successful diversification achieved through the Akoya acquisition, expanding into oncology and immunology, and praised the talent and synergy realization. He noted a holistic review of product development to prioritize ROI-driven growth. CFO Vandana Sriram confirmed a continuous cadence of new assay launches throughout 2026, building on 2025's 13 new assays.
Ask follow-up questions
Fintool can predict 
QTRX's earnings beat/miss a week before the call